Skip to main content

Table 5 Grade three or four treatment-related haematological adverse events by number of patients 1

From: PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Adverse event

Group A2(n=9)

Group B3(n=6)

Group C4(n=21)

Group D5(n=6)

Gd 3

Gd 4

Gd 3

Gd 4

Gd 3

Gd 4

Gd 3

Gd 4

Leucopenia

2

-

3

1

4

6

3

-

Neutropenia

2

1

3

1

3

6

2

1

Thrombocytopenia

-

3

-

-

2

4

-

2

Anaemia

1

-

-

-

3

-

1

-

Any haematological toxicity

 

4

3

1

5

7

1

3

  1. 1Highest toxicity grade by CTCAE version 3.0 for each patient; 2 PR104 + gemcitabine.
  2. 3 PR104 + docetaxel 60; 4 PR104 + docetaxel 60 + GCSF; 5 PR104 + docetaxel 75 + GCSF.